gms | German Medical Science

78. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

16.05. - 20.05.2007, München

Identification of high risk patients for second primary and residual tumors via SELDI TOF MS

Meeting Abstract

  • corresponding author Alexandra Leipold - ENT Departement, Heidelberg, Germany
  • M. Roesch-Ely - ENT Departement, Heidelberg, Germany
  • A. Dietz - ENT Departement, Leipzig, Germany
  • F.X. Bosch - ENT Departement, Heidelberg, Germany
  • P.K. Plinkert - ENT Departement, Heidelberg, Germany

German Society of Oto-Rhino-Laryngology, Head and Neck Surgery. 78th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery. Munich, 16.-20.05.2007. Düsseldorf, Köln: German Medical Science; 2007. Doc07hno086

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hno2007/07hno086.shtml

Veröffentlicht: 8. August 2007

© 2007 Leipold et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Despite the advances in oncology the rate of residual disease and second primary head and neck tumors is still very high. The reason might be the extended biological changes of the mucosa of the whole upper aero-digestive area, not restricted to the original primary tumor site. Via SELDI TOF MS we were able to identify distant mucosal changes, which correlated with the changes of the tumorcells.

5 Biopsies were taken from each patient (9 patients without and 15 patients with carcinoma). The protein-profiles were analysed via SELDI TOF MS and compared with profiles from other tumorbiopsies. The data was updated with the clinical parameters and a follow up after two years.

After identifying the average peak-intensities the protein profiles were colour coded and sorted in three different groups (class prediction analysis). Patients without tumor showed only “healthy” protein profiles, 10 of 15 patients with tumor were identified as such, although the histology of these biopsies was unsuspicious. We found field cancerization as well as skip lesions.

SELDI TOF MS seems to be an innovative method to identify patients at risk for residual disease and second primary carcinoma. The biopsies of macroscopic healthy mucosa are able to identify molecular changes. This gives the opportunity to identify patients at risk for extended therapeutic consequences and better clinical surveillance.